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AbsTrACT
background High- sensitivity C reactive protein (hsCRP) 
has been proposed as a marker of incident cardiovascular 
disease and vascular mortality, and may also be a marker 
of non- vascular mortality. However, most evidence comes 
from either North American or European cohorts. The 
present proposal aims to investigate the association of 
hsCRP with the risk of all- cause mortality in a multiethnic 
Brazilian population.
Methods Baseline data (2008–2010) of a cohort of 14 
238 subjects participating in the Brazilian Longitudinal 
Study of Adult Health were used. hsCRP was assayed 
with immunochemistry. The association of baseline 
covariates with all- cause mortality was calculated by Cox 
regression for univariate model and adjusted for different 
confounders after a mean follow- up of 8.0±1.1 years. 
The final model was adjusted for age, sex, self- rated race/
ethnicity, schooling, health behaviours and prevalent 
chronic disease.
results The risk of death increased steadily by 
quartiles of hsCRP, from 1.45 (95% CI 1.05 to 2.01) in 
quartile 2 to 1.95 (95% CI 1.42 to 2.69) in quartile 4, 
compared with quartile 1. Furthermore, the persistence 
of a significant graded association after the exclusion of 
deaths in the first year of follow- up suggests that these 
results are unlikely to be due to reverse causality. Finally, 
the HR was unaffected by the exclusion of participants 
who had self- reported medical history of diabetes, cancer 
and chronic obstructive pulmonary disease.
Conclusions Our study shows that hsCRP level is 
associated with mortality in a highly admixed population, 
independent of a large set of lifestyle and clinical 
variables.
InTroduCTIon
C reactive protein (CRP), which is synthesised 
by the liver, is a biomarker of the innate immune 
response. Its main function is as defence against 
bacteria and clearance of damaged cells. Circulating 
CRP is not proinflammatory in healthy subjects, 
but undergoes conformational changes when tissue 
is damaged, activating complement and immune 
response. It is regulated by proinﬂammatory cyto-
kines including interleukin (IL)-6, IL-1 and tumour 
necrosis factor-α.1 2 CRP has been shown to be a 
useful marker for presence of infection and of 
severity of trauma, but more recently the develop-
ment of methodologies has allowed for the detec-
tion of high- sensitivity C reactive protein (hsCRP), 
which is associated with chronic non- communicable 
diseases (NCD), in which there is an activation of 
the proinflammatory state. These include type 2 
diabetes, obesity, metabolic syndrome and athero-
sclerosis.3 4
Previous studies have shown that hsCRP level 
is independently associated with incident cardio-
vascular disease (CVD). In observational epide-
miological studies, elevated plasma hsCRP levels 
are consistently associated with increased risk of 
ischaemic heart disease and ischaemic cerebrovas-
cular disease. Studies carried out among individuals 
with no history of CVD demonstrate that hsCRP 
is a strong predictor of future vascular events, 
and in most cases has proven independent of the 
major ‘traditional’ risk factors (sex, age, smoking, 
cholesterol level, blood pressure and diabetes).5–7 
However, most evidence comes from either North 
American or European cohorts. A very recent 
study demonstrates that higher hsCRP significantly 
increased the risk of developing CVD in a Chinese 
population.8
Monitoring and maintaining ideal hsCRP levels 
can be an important therapeutic target and can be 
used as criteria for primary and secondary preven-
tion.9–12 Low- grade systemic inflammation can be 
defined by hsCRP level, and decreased inflamma-
tion may reduce atherothrombotic risk. hsCRP 
values of 1–3 mg/L are considered a marker of 
moderate cardiovascular risk and levels of >3 mg/L 
may indicate higher cardiovascular risk.13
The relation of hsCRP with all- cause mortality 
was also evaluated in The Emerging Risk Factors 
Collaboration (2010), which shows that the risk 
ratio (RR) for vascular mortality per threefold 
higher loge CRP concentration was 1.71 (1.53–
1.91) when initially adjusted for age and sex only, 
and 1.55 (1.37–1.76) when adjusted further for 
conventional risk factors. RRs for non- vascular 
mortality were 1.55 (1.41–1.69) and 1.54 (1.40–
1.68), respectively, for each adjustment.7 The recent 
Whitehall II study suggests that IL-6 and hsCRP are 
more important predictors of mortality than alpha-
1- acid glycoprotein for cardiovascular, cancer and 
all- causes- related mortality.14
The causal role of the different inflammatory 
biomarkers in the incidence of NCD is difficult to 
determine because inflammatory responses may 
be due to a multiplicity of factors, such as tobacco 
consumption, overweight and obesity, physical 
inactivity, persistent and/or transient infection, 
ethnicity, and socioeconomic condition,5 15–17 all 
associated with mortality.
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The present proposal aims to investigate the association of 
hsCRP with the risk of all- cause mortality in the Brazilian Longi-
tudinal Study of Adult Health (ELSA- Brasil) cohort. This analysis 
may help extend previous observations to a unique multiethnic 
and highly admixed population.
MeThods
Population
The ELSA- Brasil is a large, multicentre, prospective cohort study 
designed primarily to identify the risk factors and the natural 
history of diabetes and CVD in the country. A total of 15 105 
participants, who are government employees from universities 
and research institutions located in six different states, took 
part. All active or retired employees of these institutions, aged 
between 35 and 74 years, were eligible for the study. Exclusion 
criteria included current or recent (<4 months prior to the first 
interview) pregnancy, intention to quit working at the institution 
in the near future, severe cognitive or communication impair-
ment, and, if retired, residence outside the metropolitan area of 
a study centre. All participants answered a comprehensive ques-
tionnaire including questions about their general health condi-
tions, family health issues, medication use, smoking, alcohol 
consumption, physical activity and mental health. In addition, 
they underwent a series of clinical and laboratory tests. Base-
line examination was performed between 2008 and 2010. 
Repeated interviews and examinations are conducted every 
3–4 years thereafter. The details of the study methodology, 
including design, eligibility criteria and the cohort’s profile, have 
been previously described.18 Of the 15 105 participants of the 
ELSA- Brasil baseline study, 683 outliers were excluded due to 
hsCRP levels greater than 10 mg/L, and 184 were removed due 
to missing information for self- rated race. A total of 14 238 indi-
viduals remained in our data set.
biomarkers as measure of exposure
All biochemical analyses were assayed from fasting serum samples 
collected between 07:30 and 10:30 in 2008–2010. hsCRP was 
assayed with immunochemistry (nephelometry) using BN II 
(Siemens). For analytical purposes, the levels were equally split 
into four groups (quartiles).
All-cause mortality as measure of outcome
All- cause mortality data up to December 2017 were collected 
from annual telephone monitoring and confirmed by death 
certificate.18
Covariates
Demographics
Demographic information included age, sex, schooling (defined 
by incomplete elementary: <8 years; complete elementary: 8–11 
years; complete high school: 11–14 years; and university degree: 
≥15 years) and self- rated race/ethnicity (defined by white, black, 
‘brown’ or of mixed colour, native indigenous, and Asian ethnicity).
Health behaviour
Health behaviours included self- reported alcohol consumption 
(categorised as excessive: men ≥210 g alcohol/week, women 
≥140 g alcohol; moderate: men <210 g alcohol/week, women 
<140 g alcohol; and none), smoking status (current, former and 
never smoker), physical activity level (low, moderate or high, 
based on the International Physical Activity Questionnaire), 
and fruits and vegetables consumption (a food frequency ques-
tionnaire was applied in order to evaluate participants’ usual 
consumption in the previous 12 months), and body mass index 
(BMI, kg/m²) was used as a continuous variable.
History of chronic disease
This included history of diabetes mellitus (DM), classified using 
blood glucose (fasting plasma glucose ≥126 mg/dL or ≥200 mg/
dL, 2 hours after overload with 75 g anhydrous glucose) or glycated 
haemoglobin ≥6.5% threshold measurements defined by the 
American Diabetes Association, or by self- reported diagnosis or 
reported use of insulin or hypoglycaemic medication identified in 
the baseline survey of the ELSA study; systolic blood pressure (mm 
Hg) obtained as the mean of the last two out of three measure-
ments taken 5 min apart, and used as a continuous variable; use 
of antihypertensive drugs; and CVD, defined based on report of 
coronary revascularisation or of a medical diagnosis of myocar-
dial infarct and/or stroke and/or heart failure. Finally, we included 
self- reported diagnosis of cancer (CA), chronic obstructive pulmo-
nary disease (COPD) and presence of depression over the previous 
7 days, assessed through the adapted Brazilian Portuguese version 
of the Clinical Interview Schedule- Revised, which is a structured 
interview for measurement and diagnosis of non- psychotic psychi-
atric morbidity in community and primary care settings.
statistical analysis
The demographic and clinical characteristics of participants are 
expressed as frequencies with proportions for categorical variables, 
and median with IQR or mean with SD for continuous variables. 
We examined participants’ characteristics by sex. The association 
of baseline covariates with all- cause mortality was calculated by 
Cox regression for univariate model. The association of baseline 
covariates with quartiles of hsCRP was calculated by analysis of 
variance for continuous variables and Pearson’s χ2 for categorical 
variables. Kaplan- Meier method was used to estimate the risk of 
fatal event, and differences in curves were tested by log- rank test. 
Finally, Cox regression analysis was used to explore the associa-
tion between hsCRP and all- cause mortality, adjusted for different 
confounders. Results are expressed as HR and 95% CI. Testing the 
proportional hazard assumption suggested no violation of propor-
tionality. The first model was adjusted for age, while the second 
model for age and sex. In the third model we adjusted for self- rated 
race/ethnicity and BMI, and in the fourth model we adjusted for 
schooling and health behaviours (alcohol consumption, smoking 
status, physical activity level, fruits and vegetables consumption). 
In the final model we included all covariates: systolic blood pres-
sure, use of antihypertensive drugs and prevalent chronic disease 
(DM, depression, CVD, CA, COPD). The area under the curve 
(AUC) was used to estimate improvement in risk discrimination 
of hsCRP. Sensitivity analyses were also performed to exclude bias 
due to reverse causality (model 5 after exclusion of deaths in the 
first year) and bias due to self- reported medical history of DM, CA 
and COPD. The level of significance was set at p<0.05. Statistical 
analyses were performed using STATA V.15.1 and R V.3.5.3 statis-
tical software packages.
resulTs
A total of 14 238 individuals were included in the final analysis, 
444 (3.12%) of whom died over a mean follow- up of 8.0±1.1 
years (death at a minimum of 16 days and maximum of 9.8 
years).
The sociodemographic, behavioural, comorbidity and labo-
ratory characteristics of participants stratified by sex are shown 
in table 1. The mean age was 52 years at baseline (range 34–75 
years). There was a slight predominance of women (54.0%) and 
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Table 1 Baseline characteristics of participants in the ELSA- Brasil cohort
Characteristics
Population
Total
n=14 238 (100%)
Female
n=7693 (54%)
Male
n=6545 (46%)
Age (years), mean (SD) 52 (9.0) 51.9 (8.8) 52.0 (9.3)
BMI (kg/m2), mean (SD) 26.8±4.5 26.8±4.8 26.9±4.2
Self- rated race/ethnicity, n (%)
  White 7471 (52.5) 3991 (51.9) 3480 (53.2)
  Mixed (‘pardo’) 4007 (28.1) 2052 (26.7) 1995 (29.9)
  Black 2248 (15.8) 1352 (17.6) 896 (13.7)
  Asian 363 (2.5) 237 (3.1) 126 (1.9)
  Indigenous 149 (1.1) 61 (0.8) 88 (1.3)
Level of education, n (%)
  University degree 7540 (53.0) 4240 (55.1) 3300 (50.4)
  Complete high school 4916 (34.5) 2743 (35.7) 2173 (33.2)
  Complete elementary school 953 (6.7) 407 (5.3) 546 (8.3)
  Incomplete elementary school 829 (5.8) 303 (3.9) 526 (8.0)
Smoking, n (%)
  Never 8146 (57.2) 6021 (79.4) 4723 (73.2)
  Former 4247 (29.8) 1143 (15.1) 1141 (17.7)
  Current 1844 (13.0) 418 (5.5) 587 (9.1)
Physical activity*, n (%)
  Low 10 744 (76.6) 6021 (79.4) 4723 (73.2)
  Moderate 2284 (16.3) 1143 (15.1) 1141 (17.7)
  High 1005 (7.1) 418 (5.5) 587 (9.1)
Alcohol consumption†, n (%)
  None 7354 (51.7) 4893 (63.7) 2461 (37.6)
  Moderate 5826 (40.9) 2520 (32.8) 3306 (50.5)
  Excessive 1048 (7.4) 271 (3.5) 777 (11.9)
Daily consumption of fruits, n (%) 8135 (57.2) 4992 (65.0) 3143 (48.1)
Daily consumption of vegetables, n (%) 7378 (51.9) 4419 (57.5) 2959 (45.3)
Diabetes‡, n (%) 2378 (16.7) 1079 (14.0) 1299 (19.9)
Systolic pressure§ (mm Hg), mean (SD) 121 (17.3) 117 (16.8) 125 (16.8)
CVD¶, n (%) 668 (4.7) 295 (3.8) 373 (5.7)
History of cancer**, n (%) 633 (4.4) 371 (4.8) 262 (4.0)
History of COPD††, n (%) 279 (1.9) 162 (2.1) 117 (1.7)
hsCRP (mg/L), median (25%–75%) 1.39 (0.70–3.02) 1.54 (0.75–3.39) 1.25 (0.66–2.55)
Some characteristics do not total 100% due to loss of information.
*Physical activity based on the International Physical Activity Questionnaire.
†Excessive drinker (men ≥210 g alcohol/week; women ≥140 g alcohol/week).
‡Diabetes mellitus: defined according to the American Diabetes Association criteria or by self- report of previous diagnosis of diabetes mellitus and/or use of insulin or oral hypoglycaemic agents.
§Average blood pressure from three measurements.
¶CVD: defined based on the report of coronary revascularisation, or of a medical diagnosis of myocardial infarct and/or stroke and/or heart failure.
**Cancer: defined by self- report.
††COPD: defined by self- report.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; hsCRP, high- sensitivity C reactive protein.
self- declared white ethnic origin (52.5%), and most participants 
had completed higher education (53.0%) and had never smoked 
(57.2%) (table 1).
Significant differences were observed in baseline characteris-
tics in the population ranked by quartiles of hsCRP, as shown in 
table 2. Comorbidities such as DM, depression, CVD and COPD 
and health behaviours such as current smoking and low physical 
activity were progressively more common with increasing levels of 
hsCRP. Also, the proportion of women increased with increasing 
levels of hsCRP (table 2).
The Cox regression models revealed a consistent and indepen-
dent association between hsCRP and death from all causes even 
after adjusting for all sets of confounders (model 5; table 3). The 
calculated AUC without hsCRP in the fully adjusted model (model 
5) was 0.793 and with hsCRP was 0.797: net reclassification 
improvement analyses (NRI) (95% CI): 0.1013 (0.0063 to 0.1962) 
(p=0.036); and integrated discrimination improvement (IDI) 
(95% CI): 0.0026 (0.0006 to 0.0046) (p=0.010).
In the sensitivity analysis, we found no evidence on the influ-
ence of bias due to self- reported medical history of DM, CA 
and COPD. The HR for hsCRP in model 5 after exclusion of 
3086 self- rated DM, CA and COPD, with 226 (2.5%) deaths, 
was 1.71 (95% CI 1.11 to 2.60), 1.57 (95% CI 1.01 to 2.43) 
and 2.20 (95% CI 1.42 to 3.39) for those in the second, third 
and highest quartiles, respectively. A total of 23 deaths (0.2%) 
were in the first year of follow- up. The HR for hsCRP in model 
5 after exclusion of deaths in the first year was 1.40 (95% CI 
1.01 to 1.95), 1.50 (95% CI 1.08 to 2.08) and 1.92 (95% CI 
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Table 2 Baseline covariates by hsCRP quartiles
Characteristics
hsCrP (mg/l)
P value
Quartile 1
(0.09–0.70)
n=3575
Quartile 2
(0.70–1.39)
n=3542
Quartile 3
(1.39–3.02)
n=3575
Quartile 4
(3.02–10.0)
n=3541
Sex 0.000*
  Female, % 49.8 50.5 53.5 62.4
  Male, % 50.2 49.5 46.5 37.6
Age (years), mean (SD) 50.0
(44.0–57.0)
51.0
(45.0–58.0)
52.0
(46.0–59.0)
52.0
(46.0–58.0)
0.000†
BMI (kg/m2), mean (SD) 25.9
(23.6–28.5)
27.1
(24.6–30.0)
28.7
(25.5–32.1)
0.000†
Self- rated race/ethnicity, % 0.000*
  White 53.9 53.9 53.1 48.9
  Mixed 27.8 27.8 28.3 29.3
  Black 14.1 14.1 15.8 19.4
  Asian 2.9 2.9 1.8 1.4
  Indigenous 1.3 1.3 1.1 1
Level of education, % 0.000*
  University degree 59.6 55.3 50.8 46
  Complete high school 30.9 33.4 35.7 38.2
  Complete elementary school 5.3 6 7.1 8.3
  Incomplete elementary school 4.1 5.3 6.4 7.5
Smoking, % 0.000*
  Never 62.4 57.9 54.8 53.7
  Former 27.9 30 31.5 29.9
  Current 9.6 12.1 13.7 16.5
Physical activity‡, % 0.000*
  Low 70.3 75.6 78.5 81.8
  Moderate 19.2 17.6 15.1 13.3
  High 10.5 6.8 6.4 4.9
Alcohol consumption§, % 0.000*
  None 50.7 50.1 50.7 55.2
  Moderate 42.7 42.7 41.4 37
  Excessive 6.6 7.2 7.9 7.8
Daily consumption of fruits, % 0.141*
  Yes 58.4 57.9 56.4 56.1
  No 41.6 42.1 43.6 43.9
Daily consumption of vegetables, % 0.001*
  Yes 52.8 53.7 51.9 49.1
  No 47.2 46.3 48.1 50.9
Diabetes¶, % 0.000*
  Yes 10.6 13.2 18.3 24.7
  No 89.4 86.8 81.7 75.3
Systolic pressure (mm Hg), mean (SD) 116
(106–126)
118
(109–130)
120
(110–132)
122
(111–133)
0.000*
CVD**, % 0.017*
  Yes 4.1 4.3 4.9 5.5
  No 95.9 95.7 95.1 94.5
Depression, % 0.001*
  Yes 3.1 4.1 4.8 4.8
  No 96.9 95.9 95.2 95.2
History of cancer††, % 0.612*
  Yes 4.1 4.4 4.6 4.7
Continued
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Characteristics
hsCrP (mg/l)
P value
Quartile 1
(0.09–0.70)
n=3575
Quartile 2
(0.70–1.39)
n=3542
Quartile 3
(1.39–3.02)
n=3575
Quartile 4
(3.02–10.0)
n=3541
  No 95.9 95.6 95.4 95.3
History of COPD‡‡, % 0.000*
  Yes 1.3 1.7 2.1 2.8
  No 98.7 98.3 97.9 97.2
Some covariates do not total 100% due to loss of information.
*P value for Pearson’s χ2.
†P value for analysis of variance.
‡Physical activity based on the International Physical Activity Questionnaire.
§Excessive drinker (men ≥210 g alcohol/week; women ≥140 g alcohol/week).
¶Diabetes mellitus: defined according to the American Diabetes Association criteria or by self- report of previous diagnosis of diabetes mellitus and/or use of insulin or oral hypoglycaemic 
agents; average blood pressure from three measurements.
**CVD: defined based on the report of coronary revascularisation, or of a medical diagnosis of myocardial infarct and/or stroke and/or heart failure.
††Cancer: defined by self- report.
‡‡COPD: defined by self- report.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; hsCRP, high- sensitivity C reactive protein.
Table 2 Continued
Table 3 Association of hsCRP (quartiles) with all- cause mortality 
over a mean follow- up of 8.0±1.1 years
Models
Total
n=14 238
(100%)
deaths
n=444
(3.12%)
hsCrP (mg/l)
Quartile 1
hr 
(reference)
Quartile 2
hr (95% CI)
Quartile 3
hr (95% CI)
Quartile 4
hr (95% CI)
Model 1* 1.0 1.43
(1.05 to 1.96)
1.65
(1.22 to 2.23)
2.23
(1.67 to 2.98)
Model 2† 1.0 1.45
(1.06 to 1.99)
1.74
(1.28 to 2.35)
2.47
(1.84 to 3.30)
Model 3‡ 1.0 1.47
(1.07 to 2.02)
1.75
(1.29 to 2.39)
2.43
(1.80 to 3.30)
Model 4§ 1.0 1.45
(1.05 to 2.01)
1.61
(1.17 to 2.22)
2.08
(1.52 to 2.85)
Model 5¶ 1.0 1.45
(1.05 to 2.01)
1.54
(1.11 to 2.13)
1.95
(1.42 to 2.69)
*Model 1: adjusted for age.
†Model 2: model 1 and sex.
‡Model 3: model 2 and ethnicity and body mass index.
§Model 4: model 3 and level of education, alcohol consumption, smoking status, physical activity level, and fruits and 
vegetables consumption.
¶Model 5: model 4 and systolic blood pressure, use of antihypertensive drugs, diabetes mellitus, depression, chronic 
obstructive pulmonary disease, cardiovascular disease and cancer.
hsCRP, high- sensitivity C reactive protein.
p-value: <0.001
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Figure 1 Kaplan- Meier cumulative hazard for all- cause mortality 
according to high- sensitivity C- reactive protein (mg/dL) categories 
(quartiles).
1.39 to 2.65) for those in the second, third and highest quartiles, 
respectively.
The Kaplan- Meier mortality curve demonstrates that there is 
an increase in mortality with increasing quartiles of hsCRP levels 
(see figure 1; p<0.001, log- rank test).
dIsCussIon
In this study, we investigated whether hsCRP predicts all- cause 
mortality in a prospective analysis of middle- aged Brazilian men 
and women. Our results show that the risk of all- cause mortality 
increases progressively with increasing levels of hsCRP. The 
results of our study not only confirm an association between 
hsCRP and all- cause mortality but also show that it is inde-
pendent of possible confounders associated with either risk of 
inflammation or pre- existing chronic disease. Furthermore, the 
persistence of a significant graded association after the exclusion 
of deaths in the first year of follow- up suggests that these results 
are unlikely to be due to reverse causality. Finally, the HR was 
unaffected by the exclusion of participants who had self- reported 
medical history of DM, CA and COPD. Addition of hsCRP to 
the fully adjusted model resulted in an increase in the AUC from 
0.793 to 0.797, and the NRI and IDI values indicate that the 
hsCRP is a significant predictor of risk. However, there is some 
debate about the use and reporting of these measures.19 20 There-
fore, cautions are needed when interpreting these results.
strengths and limitations
The strengths of this study include its large sample size with diverse 
demographic, regional and socioeconomic characteristics, inclu-
sion of several potential confounders, long follow- up period, and 
highly standardised biochemical assessment of exposure and certi-
fied deaths. Our results are consistent with previous studies from 
different international cohorts showing that hsCRP, as well as other 
inflammatory markers, is associated with age, gender, ethnic back-
ground,17 21 BMI,15 smoking22 and chronic diseases.7 23–27
The present study has potential limitations too. Inflammatory 
markers may have a diurnal variation. In our study however blood 
samples were collected in a narrow time window (from 07:30 to 
10:30); in a previous study, in a comparable British population 
study, we observed no significant effect of such variation on esti-
mates of associations.28 While the level of hsCRP was assessed 
using a single measurement, this is consistent with most previous 
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What is already known on this subject
 ► High- sensitivity C reactive protein (hsCRP) has been 
proposed as a marker of incident cardiovascular disease and 
vascular mortality, and may also be a marker of non- vascular 
mortality.
 ► Most evidence comes from high- income and mainly North 
American or European cohorts.
What this study adds
 ► This study extends previous research in this area and 
demonstrates that the risk of all- cause mortality increases 
progressively with increasing levels of hsCRP in a middle- 
income South American population.
 ► The association is independent of age, sex, body mass index, 
self- rated race/ethnicity, schooling, alcohol consumption, 
smoking status, physical activity level, and fruits and 
vegetables consumption.
 ► Significant graded association persists after exclusion of 
deaths in the first year of follow- up and suggests that these 
results are unlikely to be due to reverse causality.
 ► The HR was unaffected by the exclusion of participants who 
had self- reported medical history of diabetes, depression, 
cancer and chronic obstructive pulmonary disease.
 ► The current results may point to an important marker of risk 
for the Brazilian population that could identify groups which 
may benefit from preventive strategies.
 ► Further studies are still required to determine whether 
hsCRP is simply a marker of underlying systemic response to 
inflammation or is a contributing cause.
population studies of inflammatory biomarkers.14 21 24 ELSA- 
Brasil is conducted in six of Brazil’s state capitals and consisted 
of university and research institute employees with stable 
employment and a notably high educational achievement; thus, 
the prevalence and incidence rates found cannot be generalised 
to Brazil’s overall adult population. However, this fact does 
not undermine our findings regarding the association between 
hsCRP and mortality, as most scientific evidence on risk factors 
for mortality comes from occupational cohorts, such as the 
British Doctors, or highly community- based ones, such as the 
Framingham Heart Study.29 30 Finally, we assessed only all- cause 
mortality, so we are unable to report on associations with cause- 
specific deaths.
Possible mechanisms
Inflammatory processes play an important role in the develop-
ment of NCDs. The innate and adaptive immune responses have a 
pivotal role in the initiation, progression and clinical consequences 
of atherosclerotic diseases.10 11 31 Components of the immune 
system are also altered in obesity and type 2 DM; these immuno-
logical changes and alterations in the levels of specific cytokines 
and chemokines suggest that inflammation participates in the 
pathogenesis of DM.26 Finally, previous studies have also found an 
association between hsCRP levels and risk of CA (lung, colorectal, 
skin and bladder), with progression and survival of patients with 
pancreatic, oesophageal, prostate and colorectal CA.27
CRP is a biomarker of the innate immune response, its main 
function being as defence against bacteria and clearance of damaged 
cells, and it is therefore unclear as to whether CRP is simply a 
marker of underlying systemic response to inflammation or is 
itself a directly contributing factor to such disorders. The concen-
tration of hsCRP, a non- specific marker of acute- phase inflamma-
tory response, is predictive of future cardiovascular morbidity.5–7 
Genetic studies indicate that about 50% of the individual variance 
in baseline CRP concentration is genetic and largely attributable 
to non- coding polymorphisms in the CRP gene.1 3 7 11 The other 
major determinant, independent of genetic factors, is the level of 
adiposity, especially central abdominal obesity.15 25 32 33
CRP binds to low- density lipoprotein cholesterol, and it has 
been detected in atherosclerotic plaques, which raises the possi-
bility that CRP may play a direct causal role.34 35 Moreover, the 
recent CANTOS (Canakinumab Anti- inflammatory Thrombosis 
Outcomes Study) has studied 10 061 patients in 39 countries 
between 2011 and 2017 with stable postmyocardial infarction but 
with ‘residual inflammatory risk’ (defined as persistent elevations 
of hsCRP >2 mg/L). Anti- inflammatory (canakinumab, a fully 
human anti- IL- 1beta monoclonal antibody) therapy lowered the 
inflammatory biomarkers (IL-6 and hsCRP) of participants by 
35%–40% when compared with placebo, effects that led to a 17% 
reduction in rates of recurrent heart attack, stroke, urgent need 
for revascularisation or cardiovascular death.12 On the other hand, 
in the 4786- patient Cardiovascular Inflammation Reduction Trial, 
low- dose methotrexate as compared with placebo did not reduce 
IL-1, IL-6 or hsCRP, as well as cardiovascular event rates.36
Inflammation can affect CA development and progression 
through several pathways. These include altered antiapoptotic 
signalling, increased angiogenesis and levels of DNA adduct forma-
tion, but it remains to be seen if hsCRP is a risk marker for CA 
progression or if it is causally related.27
Implications
The level of hsCRP is currently used for global cardiovascular 
risk prediction, as a tool to determine risk of DM and metabolic 
syndrome, and as a method to monitor and guide statin therapy,37 
and may be important for monitoring CA progression and 
survival.27 Our results in this new large admixed cohort are consis-
tent with previous studies that indicate that proinflammatory 
biomarkers like hsCRP are independently associated with mortality 
risk.37–39 Although the mortality rate in Brazil has declined between 
1990 and 2015, the proportion of deaths attributable to NCDs 
has increased from 59.6% in 1990 to 75.8% in 2015, with CVD 
being responsible for 31.2% and CA for 17.4% of all deaths.40 The 
current results may point to an important marker of risk for the 
Brazilian population.
ConClusIons
Our study shows that hsCRP levels, independent of a large set of 
lifestyle and clinical variables, could affect mortality prediction in 
a highly admixed population. The current results may point to an 
important marker of risk for the Brazilian population that could 
identify groups which may benefit from preventive strategies. 
Further studies are still required to determine whether hsCRP is 
simply a marker of underlying systemic response to inflammation 
or is a contributing cause.
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